Anebulo Pharmaceuticals annual operating expenses
2021
2022
2023
2024
2025
Anebulo Pharmaceuticals Operating Expenses Growth & History (ANEB)
Anebulo Pharmaceuticals's operating expenses was $9.2M for fiscal 2025.
View full Anebulo Pharmaceuticals company overviewAnebulo Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $9.2M | $914,726 | +11.01% |
| 2024 | 2024-06-30 | $8.3M | −$3.5M | −29.49% |
| 2023 | 2023-06-30 | $11.8M | $5.0M | +72.50% |
| 2022 | 2022-06-30 | $6.8M | $3.2M | +89.03% |
| 2021 | 2021-06-30 | $3.6M | — | — |
Anebulo Pharmaceuticals quarterly operating expenses
Q2.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2025-12-31 | $2.6M | $31,759 | +1.23% |
| Q1 2026 | 2025-09-30 | $2.3M | −$151,864 | −6.30% |
| Q4 2025 | 2025-06-30 | $2.3M | $990,517 | +73.90% |
| Q3 2025 | 2025-03-31 | $1.9M | $228,071 | +13.70% |
| Q2 2025 | 2024-12-31 | $2.6M | −$172,308 | −6.24% |
| Q1 2025 | 2024-09-30 | $2.4M | −$131,554 | −5.17% |
| Q4 2024 | 2024-06-30 | $1.3M | −$1.2M | −46.26% |
| Q3 2024 | 2024-03-31 | $1.7M | −$1.2M | −41.89% |
| Q2 2024 | 2023-12-31 | $2.8M | −$1.1M | −27.61% |
| Q1 2024 | 2023-09-30 | $2.5M | −$68,369 | −2.62% |
| Q4 2023 | 2023-06-30 | $2.5M | $168,905 | +7.26% |
| Q3 2023 | 2023-03-31 | $2.9M | $984,397 | +52.37% |
| Q2 2023 | 2022-12-31 | $3.8M | $2.7M | +255.99% |
| Q1 2023 | 2022-09-30 | $2.6M | $1.1M | +67.99% |
| Q4 2022 | 2022-06-30 | $2.3M | −$159,221 | −6.41% |
| Q3 2022 | 2022-03-31 | $1.9M | $1.3M | +240.43% |
| Q2 2022 | 2021-12-31 | $1.1M | $746,551 | +230.01% |
| Q1 2022 | 2021-09-30 | $1.6M | $1.3M | +516.19% |
| Q4 2021 | 2021-06-30 | $2.5M | $2.3M | +1333.34% |
| Q3 2021 | 2021-03-31 | $552,131 | — | — |
| Q2 2021 | 2020-12-31 | $324,571 | — | — |
| Q1 2021 | 2020-09-30 | $252,346 | — | — |
| Q2 2020 | 2020-06-30 | $173,351 | — | — |
Anebulo Pharmaceuticals operating expenses trends
Between the periods ended 2021-06-30 and 2025-06-30, Anebulo Pharmaceuticals's operating expenses increased from $3.6M to $9.2M, a change of $5.6M. The latest reported quarter, Q2 2026, shows $2.6M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anebulo Pharmaceuticals source filings ↗